Core Insights - Novartis shares rose nearly 2% to $132.73 following a significant deal with Relation Therapeutics valued at over $1.7 billion aimed at discovering drug targets for allergic diseases [1] Company Summary - Novartis has entered into a collaboration with UK-based biotech company Relation Therapeutics to leverage its expertise in immunodermatology and Relation's AI-driven drug discovery platform [1] - The partnership will utilize patient data, including human tissue, to uncover the genetic basis of disease manifestations [1]

Core Insights - Novartis (NVS.US) shares rose nearly 2% pre-market, reaching $132.73 [1] - Novartis has entered into a deal worth over $1.7 billion with UK biotech company Relation Therapeutics to identify drug targets for allergic diseases [1] - The collaboration aims to combine Novartis's expertise in immunodermatology with Relation's AI-driven drug discovery platform, which utilizes patient data, including human tissue, to uncover the genetic basis of disease manifestations [1]